Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Human Glucocerebrosidase (prGCD)
Human Glucocerebrosidase · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Human Glucocerebrosidase (prGCD) | DRUG | - |
Human Glucocerebrosidase is being developed for the treatment of Gaucher Disease, a rare inherited lysosomal storage disorder. It is an investigational therapy and has been studied in a Phase 1 clinical trial. It is not approved for commercial use.
Human Glucocerebrosidase targets the insulin receptor (INSR) and acts as an agonist at that receptor. This receptor interaction defines its mechanism of action as characterized in its development program for Gaucher Disease.
Human Glucocerebrosidase is being developed by Protalix BioTherapeutics, Inc., which trades under the ticker PLX. The company is the sponsor of the clinical development program for this investigational Gaucher Disease therapy.
Human Glucocerebrosidase is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The therapy remains investigational and has not been approved by the FDA.
Human Glucocerebrosidase has been evaluated in one completed Phase 1 trial, NCT00258778, titled a Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD). The trial enrolled 6 participants with Gaucher Disease and was an uncontrolled, non-randomized study.
Yes, Human Glucocerebrosidase is also known as Human Glucocerebrosidase (prGCD). The abbreviation prGCD refers to the same investigational therapy developed by Protalix BioTherapeutics for Gaucher Disease, so searches for either name refer to the same asset.